Dados do Trabalho

Título

PARATESTICULAR AND NON-GERM CELL TESTICULAR TUMORS IN A TERTIARY CANCER CENTER: A RETROSPECTIVE SERIES

Introdução

Germ cell tumors are the most common histology in intrascrotal neoplasms. Given their rarity, the literature on the remaining histological types is still scarce.

Objetivo

To describe epidemiologic, clinical and pathological features, as well as treatment patterns and outcomes of patients with non-germ cell intrascrotal cancers.

Método

Patients (pts) older than 18 years old with benign or malignant non-germ cell intrascrotal tumors from a tertiary cancer center were deemed eligible. Electronic charts were reviewed to assess pts and disease characteristics and outcomes. Descriptive statistics was used to report data. Time-to-event variables were estimated by the Kaplan-Meyer method.

Resultado

885 pts with a diagnosis of ICD-C62 from January 2009 to June 2020 were assessed for eligibility. Of those, 29 pts with non-germ cell intrascrotal neoplasms were included in this analysis (Sertoli cell tumors , N =3; Leydig cell tumors, N = 6; granulosa cell tumor, N = 1; testicular tumor of the androgenital syndrome, N = 1; mesotheliomas, N = 3; liposarcomas, N = 3; leiomyosarcomas N = 2; rhabdomyosarcomas, N = 3; spindle cell sarcomas, N = 3; lymphomas, N = 2; carcinoma of the rete testis, N = 1; primary neuroendocrine tumor of the testis, N = 1). Most of them (n=25) had localized disease at diagnosis and all patients underwent upfront orchiectomy. 4 patients had metastatic disease at diagnosis (lymphoma, N = 1; sarcomas, N = 3), all had lymph node(LN) involvement; one with concurrent non-nodal metastasis; and 6 patients developed metastatic disease after a median follow-up of 13,0 months (IQR: 5,8 – 33,05) (Leydig, N=1; mesothelioma, N=2; sarcomas, N=3). Most common metastatic sites were LN, N=8 (80%); lung, N=4 (40%); bone, N=3 (30%); adrenal gland, N=2 (20%); peritoneum, N=1 (10%) and skin, N=1 (10%). Nine (90%) received systemic palliative treatment: vincristine, doxorubicin and cyclophosphamide for rhabdomyosarcomas (N=3), cisplatin plus pemetrexed for mesotheliomas (N=2), doxorubicin for liposarcomas (N=2), doxorubicin plus ifosfamide for liposarcoma (N=1) and doxorubicin, vincristine, cyclophosphamide, and prednisone plus rituximab for lymphoma (N=1). Surgical resection of a single Leydig cell tumor lung metastasis was performed.

Conclusão

Paratesticular and non-germ cell testicular cancers are extremely rare diseases, with relatively good prognosis at early stages depending on the underlying histology. Most patients with metastatic disease had sarcoma.

Palavras-chave

Testicular Cancer, Paratesticular Cancer, Non-Germ Cell Intrascrotal Tumor